Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25218246 | 0.82 | KMT2A (0.44) | CYP3A4CYP2D6KMT2AMEN1USP2 | |
| SCHEMBL7042751 | 0.82 | HPGD (0.39) | CYP3A4CYP2D6KMT2AMEN1TSHR | |
| SCHEMBL111724 | 0.81 | ALDH1A1 (0.47) | CYP3A4CYP2D6KMT2AMEN1USP2 | |
| SCHEMBL1216706 | 0.81 | TSHR (0.47) | CYP3A4CYP2D6KMT2AMEN1USP2 | |
| SCHEMBL1698031 | 0.81 | TSHR (0.53) | CYP3A4CYP2D6KMT2AMEN1USP2 | |
| SCHEMBL3159903 | 0.80 | AOC3 (0.44) | HPGDLMNAKDM4ETAAR1L3MBTL1 | |
| SCHEMBL7043843 | 0.80 | LOXL2 (0.40) | CYP3A4CYP2D6TSHRBLMHPGD | |
| SCHEMBL7450074 | 0.79 | TSHR (0.46) | CYP3A4CYP2D6KMT2AMEN1USP2 | |
| SCHEMBL11043374 | 0.79 | TSHR (0.46) | CYP3A4CYP2D6KMT2AMEN1USP2 | |
| SCHEMBL27773246 | 0.79 | MAPT (0.46) | CYP3A4CYP2D6KMT2AMEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682105-A4 | N-UREIDOALKYL-AMINO COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2008-12-24 | — | — | EP | disclosed |
| US-7291744-B2 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1682105-A2 | N-UREIDOALKYL-AMINO COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20050153970-A1 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-07-14 | — | — | US | disclosed |
| WO-2005048932-A2 | N-UREIDOALKYL-AMINO COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
| CN-1040753-C | Pyridine derivatives and the preparation thereof | ICI PLC (GB) | 1998-11-18 | — | — | CN | disclosed |
| US-5401849-A | FOR ANTAGONIZING THE ACTIONS OF, AND INHIBITING THE SYNTHESIS OF, THROMBOXANE A2 | ZENECA LIMITED (GB) | 1995-03-28 | — | — | US | disclosed |
| EP-0329360-B1 | Pyridine derivatives | ICI PLC (GB) | 1994-08-03 | — | — | EP | disclosed |
| US-5248780-A | Thromboxane inhibitors | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1993-09-28 | — | — | US | disclosed |
| US-5166213-A | Antiischemic agents, cardiovascular disorders, antiasthmatics or antiinflammatory agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-11-24 | — | — | US | disclosed |
| US-4994480-A | Protecting plants, industrial materials | BAYER AKTIENGESELLSCHAFT (DE) | 1991-02-19 | — | — | US | disclosed |
| EP-0338344-A2 | Substituted triazolyl methyl carbinoles | BAYER AG (DE) | 1989-10-25 | — | — | EP | disclosed |
| CN-1035115-A | Pyridine derivate and preparation method thereof | ICI PLC (GB) | 1989-08-30 | — | — | CN | disclosed |
| EP-0329360-A2 | Pyridine derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-08-23 | — | — | EP | disclosed |
| US-4160036-A | ADRENERGIC STIMULANTS | ALLEN & HANBURYS LIMITED (GB) | 1979-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153970-A1 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | ACKR3, CCL11, GPR17 | CYP3A4 3981/4885CYP2D6 3192/4885KMT2A 4319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.